Open AccessA phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
Author(s) -
Göran Carlsson,
Anna Koumarianou,
Tormod Kyrre Guren,
J. Haux,
Panagiotis Katsaounis,
Nikolaos Kentepozidis,
Per Pfeiffer,
Morten Brændengen,
Dimitris Mavroudis,
Helena Taflin,
L. Skintemo,
Roger Tell,
Christos Papadimitriou
Publication year - 2022
Publication title -
esmo open
Language(s) - English
Resource type - Journals
ISSN - 2059-7029
DOI - 10.1016/j.esmoop.2022.100589
Subject(s) - irinotecan , bevacizumab , medicine , oxaliplatin , tolerability , pharmacokinetics , colorectal cancer , fluorouracil , adverse effect , phases of clinical research , gastroenterology , pharmacology , oncology , chemotherapy , cancer